The 2021 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium showcased a range of exciting clinical trial data and major milestones in prostate cancer. VJOncology has bought together a team of leading experts in prostate cancer to explore their insights on key updates from this meeting.

In this exclusive podcast, Neal Shore, MD, FACS, Carolina Urologic Research Center, SC was joined by Bertrand Tombal, MD, PhD, Cliniques Universataires Saint-Luc, Brussels, Belgium, Rana McKay, MD, UC San Diego Health, CA, and Robert Jones, MBChB, PhD, University of Glasgow & Beaston West of Scotland Cancer Center, Glasgow, UK.

The panel engage in an insightful discussion on the updated results from the ACIS trial in metastatic CRPC, as well as final analyses of the landmark Phase III SPARTAN, PROSPER and ARAMIS studies in non-metastatic CRPC. In addition, the panel debate the findings from the Phase III PROfound trial evaluating the PARP inhibitor olaparib and offer their perspectives on GnRH receptor antagonists, PSMA-PET and the integration of genomic profiling into practice.